Critsal B Inhaler is an essential and highly effective combination medication that provides dual-action therapy for the management of asthma and other reversible obstructive airway diseases. It contains a precise dose of Levosalbutamol (50 mcg), a fast-acting bronchodilator that provides quick relief from bronchospasm, and Beclometasone (50 mcg), a potent corticosteroid that addresses the underlying inflammation. This powerful combination not only alleviates immediate symptoms like wheezing and shortness of breath but also works to reduce swelling and irritation in the airways, providing long-term control and helping to prevent future flare-ups.
The respiratory segment of the Indian pharmaceutical market is a high-volume, high-growth sector with a consistently high demand. The rising prevalence of respiratory disorders, fueled by factors such as increasing air pollution, seasonal allergies, and lifestyle changes, ensures a continuous and robust need for effective combination therapies. Products like Critsal B Inhaler are a staple in both hospital and home-care settings, with a stable prescription base from pulmonologists and general physicians. This continuous and predictable demand guarantees a steady and reliable revenue stream, making it a strategic choice for any distributor.
We are dedicated to empowering our franchise partners with all the tools necessary for success. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, which is crucial for building trust with healthcare professionals and patients. We provide a complete promotional and marketing kit, including visual aids and product literature, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of this top-quality respiratory medicine.